HOME ABOUT PIPELINE BUSINESS DEVELOPMENT CAREERS CONTACT Our pipeline candidates address a variety of genetic orphan and neurological disorders. We focus on providing meaningful treatments for patients who suffer from these diseases. †CUTX-101 designations: Fast Track, Orphan Drug, Rare Pediatric Disease, Breakthrough Therapy (Sentynl acquired exclusive rights to CUTX-101 and is supporting its development) ‡STI-102 designation: Fast Track © 2015-2021 by Sentynl Therapeutics, Inc. All Rights Reserved. Terms of Use Privacy Report an Adverse Event Corporate Compliance